文献速递糖尿病

澳大利亚社会经济劣势与偏远程度和2型糖尿病药物获取的关联:全国注册研究

The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study.
PubMed 文献 · Diabetologia · 2020-10-20

本研究基于澳大利亚国家糖尿病服务计划(NDSS)2007至2015年1,203,317例2型糖尿病注册者,链接药品索赔数据库,分析社会经济劣势与偏远程度对新型降糖药获取的影响。结果显示,最劣势地区人群在DPP4i、GLP-1RA和SGLT2i上市首年获取率均低于最优势地区,DPP4i与SGLT2i的差异随时间消退但GLP-1RA持续显著;偏远地区与主要城市间的差异持续至2015年。

要点

  • 最劣势地区人群新型降糖药上市首年获取率低于最优势地区。
  • DPP4i与SGLT2i的社会经济差异随时间消退,GLP-1RA持续显著。
  • 偏远地区与主要城市间新型降糖药获取差异持续至2015年。

核心结论

  • 更劣势地区2型糖尿病患者获取新型降糖药的可能性更低,该效应随时间减弱。
  • 主要城市与偏远地区之间新型降糖药获取差异显著且持续存在。

研究设计与样本

  • 全国注册研究,纳入澳大利亚NDSS注册的1,203,317例2型糖尿病患者,随访2007至2015年。
  • NDSS链接澳大利亚药品索赔数据库,分析降糖药配药趋势及社会人口学分层差异。

主要发现

  • 最劣势 vs 最优势五分位区上市首年获取DPP4i的OR(95%CI)为0.78(0.75,0.82)。
  • 最劣势 vs 最优势五分位区上市首年获取GLP-1RA的OR(95%CI)为0.65(0.60,0.71)。
  • 最劣势 vs 最优势五分位区上市首年获取SGLT2i的OR(95%CI)为0.89(0.84,0.95)。
  • 偏远地区 vs 主要城市上市首年获取DPP4i、GLP-1RA、SGLT2i的OR(95%CI)分别为0.46(0.39,0.54)、0.46(0.35,0.61)、0.71(0.59,0.84)。

关键数值与推荐

  • DPP4i与SGLT2i的社会经济劣势差异随时间消退,GLP-1RA差异持续显著。
  • 偏远地区与主要城市间获取差异持续至2015年。

临床怎么用

  • 内分泌科医生处方新型降糖药时需关注患者社会经济状况与居住地,识别获取障碍。
  • 对偏远地区及劣势人群应主动评估新型药物可及性并采取支持措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: In recent years, several new medications for the treatment of type 2 diabetes have been released and some evidence indicates sociodemographic disparity in their utilisation. We sought to investigate sociodemographic disparities in receipt of diabetes medications across Australia. METHODS: This study included 1,203,317 people with type 2 diabetes registered on the Australian National Diabetes Services Scheme (NDSS) followed from 2007 to 2015. The NDSS was linked to the Australian pharmaceutical claims database. We investigated trends in diabetes medication dispensing and variation in dispensing by sociodemographic strata. RESULTS: Compared with individuals in the least disadvantaged areas, those in the most disadvantaged quintile were less likely to receive dipeptidyl peptidase-4 inhibitors (DPP4is), glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) in the first year of availability (OR [95% CI] for most vs least disadvantaged: 0.78 [0.75, 0.82], 0.65 [0.60, 0.71] and 0.89 [0.84, 0.95], respectively). These disparities dissipated over time for DPP4is and SGLT2is but remained significant for GLP-1RAs. The OR (95% CI) of receiving DPP4is, GLP-1RAs and SGLT2is in the first year of availability for people in remote areas vs major cities was 0.46 (0.39, 0.54), 0.46 (0.35, 0.61) and 0.71 (0.59, 0.84), respectively. These disparities remained significant through to 2015. CONCLUSIONS/INTERPRETATION: People with diabetes in more disadvantaged areas are less likely to receive newer diabetes medications, although this effect decreased over time. However, there are considerable and persistent differences in receipt of newer diabetes medications between major cities and remote areas of Australia. Graphical abstract.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Morton JI, Ilomӓki J, Magliano DJ, et al. The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study. Diabetologia. 2020. PMID: 33078206. doi:10.1007/s00125-020-05304-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。